|
|
|
|
|
The Niche
|
Stem Cell & Regenerative Med Newsletter
|
|
|
|
|
|
Weekly reads: Vertex hold, new type of cell division in fish, CAR-T
|
|
|
|
I remember the first time I ever witnessed human cell division first hand and it was really excitement. I was working as a part-time tech in the Lane Lab at UC San Diego School of Medicine. We studied heart disease and grew human umbilical cord endothelial cell cultures. It was striking to see a plate of cells double in numbers …
|
|
|
|
|
|
|
|
End of FDA "grace period" impacted perinatal cell therapy biotechs
|
|
|
|
If there's one area of biologics where the FDA has been consistently busy lately it's the perinatal cell therapy space. The agency has made it clear in the last year that allogeneic birth-related cell products are often drugs requiring premarket approval. This has mainly manifested at a practical enforcement level. We've seen actions taken in regard to unproven, birth-related stem …
|
|
|
|
|
|
|
|
Review of Peter Diamandis Fountain Life clinics: more than stem cell hype?
|
|
|
|
Many of you readers know tech guru Peter Diamandis for his great X PRIZE, but he's also involved in the regenerative medicine world including a new effort called Fountain Life. Teaming up with life coach Tony Robbins and others for Fountain Life raises some red flags for me. What's in this article Peter Diamandis and Fountain Life | Stem cells rah …
|
|
|
|
|
|
